Our investigation has illuminated a new facet of TSL’s pharmacological profile, revealing its selective anti-proliferative efficacy against breast cancer cells overexpressing estrogen receptor (ER) or human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR). This evidence concerns the gene EGFR and breast carcinoma.